Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (study visits) and reply to our email (don’t re-register online) to let us know which groups(s) you are available for
- We will ring you to check your suitability and provide further information about the study.
- We will make you a screening appointment at NZCR Christchurch. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
Alopecia Areata (AA) is a complex autoimmune condition that is characterised by hair loss of the scalp, and/or the whole body, and effects approximately 2% of people worldwide.
MAX-40070 is a drug in the class known as ‘Janus kinase (JAK) inhibitors’ which are a type of medication that is able to inhibit the immune pathway that is often upregulated in autoimmune conditions. MAX-40070 is a topical application (cream) that is being developed as a potential treatment for AA. MAX-40070 may be safer and more effective than oral treatments as it will take effect directly at the site of application.
The purpose of this study is to:
• Evaluate how safe and well tolerated MAX-40070 is, following a single dose in healthy participants.
• Measure levels of MAX-40070 in the blood over time, following a single dose in healthy participants.
Study Candidtes
- Healthy males and females
- Aged 18 – 55 years
- Weigh at least 50 kg (females) or at least 55 kg (males)
- BMI 20.0 – 30.0 kg/m2
- Not taking any medications
- Don’t have any skin damage, rash, markings and/or tattoos covering your back area
What is Involved?
Overnight stays: One 3 night stay
Outpatient visits: 2 visits (including screening)
Reimbursement: $2,500 (less tax)
Route of drug administration: Topical (on skin)
Important Documents
Important documents to download and read
Please note you need to scroll through the PDF to view each cohort. If these dates don’t suit, there will be more dates coming up.